Zydus Therapeutics’ saroglitazar drug granted priority review by US FDA The Economic TimesFDA Grants Priority Review to Saroglitazar NDA for Primary Biliary Cholangitis HCPLiveZydus Therapeutics New Drug Application (NDA) for Saroglitazar to Treat Primary Biliary Cholangitis (PBC) Granted Priority Review by the US FDA Yahoo Finance
